Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Clinical Trials Innovation Research & Development

Pharma Intelligence Congratulates The CARE Awards Winners

Executive Summary

The fourth annual CARE Awards returned to Boston, Massachusetts, 2 May to once again recognize and commend key achievements across the spectrum of drug development that took place in 2018.

You may also be interested in...



R&D Successes Celebrated At 2018 CARE Awards

Informa Pharma Intelligence pays tribute to the people driving the advances in drug development and their commitments to advancing human health with the third annual CARE Awards.

R&D Successes Celebrated At 2018 CARE Awards

Informa Pharma Intelligence pays tribute to the people driving the advances in drug development and their commitments to advancing human health with the third annual CARE Awards.

A Status Check Of The Alzheimer’s Trial Landscape

Despite high-profile failures, including the recent disappointing results for Axovant Science’s Phase III MINDSET study, the trial landscape for Alzheimer’s disease remains busy.

Table

View full table

Topics

Related Companies

Tags:
Clinical Trials Innovation Research & Development
Latest Headlines

Can Organovo Leverage Its Solid Phase II Data In MASH?

Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune

Darzalex Surpasses Stelara As J&J’s Best-Selling Drug

Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company

See All
UsernamePublicRestriction

Register

SC125164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By